The $255M Bet That Wall Street Believes in Brain Drugs Again
Seaport Therapeutics just raised $255 million in an upsized IPO, pricing at the top of its range. Built by the team that sold Karuna Therapeutics to Bristol Myers Squibb for $14 billion, the company is betting it can turn brain drugs that already work into pills people can actually take.
A Quarter-Billion Dollars for a Company Most People Have Never Heard Of
Two years ago, pitching a brain drug startup to Wall Street was like bringing a salad to a barbecue. Nobody wanted it. Neuroscience trials fail constantly, endpoints are subjective, and placebo effects are brutal. Investors had largely written off the space.
Then Seaport Therapeutics walked into the room and walked out with $255 million.
The Boston-based biotech priced its Nasdaq IPO on April 30 at $18 per share, right at the top of its range. Originally, the company planned to sell about 11.8 million shares and raise somewhere around $200 million. Instead, it sold 14.16 million shares and pocketed nearly $255 million before fees. The underwriters (Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel) also snagged a 30-day option to buy another 2.1 million shares if demand keeps rolling.
That's not a company sneaking through the IPO window. That's a company kicking the door open.
The Karuna Connection
Seaport didn't appear out of nowhere, even though it was only founded in 2024. The company was built by the same team behind Karuna Therapeutics, which developed an antipsychotic called Cobenfy (KarXT) and sold to Bristol Myers Squibb for $14 billion.
The founder and CEO, Daphne Zohar, previously ran PureTech Health and co-founded Karuna. The board chair, Steven M. Paul, was Karuna's CEO and before that ran Eli Lilly's research labs, where he oversaw drugs like Cymbalta and Zyprexa. These aren't first-time founders hoping to figure it out. They've already built and sold a major CNS company.
That pedigree matters. When the same crew raises a $100 million oversubscribed Series A (co-led by ARCH Venture Partners and Sofinnova, with Third Rock Ventures as a major investor) and then immediately starts prepping for a public offering, investors pay attention. It's like a chef who already has three Michelin stars opening a new restaurant: you're going to give them the benefit of the doubt.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
What They're Actually Building
Seaport's core idea is clever. Rather than inventing brand-new drugs from scratch (expensive, risky, slow), they take proven brain-active molecules that already work but have delivery problems, and fix the delivery.
Their secret weapon is called the Glyph platform, licensed from Monash University in Australia. Think of it like a Trojan horse for drugs: it wraps known molecules in a prodrug shell that bypasses the liver on the way in, improving how much medicine actually reaches the brain while reducing liver-related side effects.
The lead candidate, GlyphAllo (SPT-300), is an oral version of allopregnanolone, a naturally occurring brain chemical. An IV form of allopregnanolone is already FDA-approved for postpartum depression (sold as Zulresso by Sage Therapeutics). The problem? Zulresso requires a 60-hour hospital infusion. Seaport wants to put essentially the same biology in a pill you take at home. They're running a Phase 2b trial in major depressive disorder.
The second program, GlyphAgo (SPT-320), tackles a different frustration. Agomelatine is an antidepressant sold in Europe as Valdoxan that works through melatonin receptors and serotonin pathways. It's effective, but it can damage your liver, requiring regular blood tests that both doctors and patients hate. Seaport's version aims to deliver the same therapeutic punch with far less liver exposure. They reported positive Phase 1 data in April 2026, and they're heading into trials for generalized anxiety disorder.
There's also a third asset, SPT-348, a non-psychedelic derivative of LSD designed for rapid-acting antidepressant effects. Yes, you read that correctly: LSD without the trip. Welcome to 2026.
Why Wall Street Showed Up
The timing of this IPO tells a bigger story about what's happening in biotech markets right now.
After two brutal years of dried-up funding and pulled offerings, the IPO window has cracked open again in 2026. More biopharma IPOs have priced above $500 million in valuation so far this year than in all of 2025, according to Morningstar. Market advisors expect roughly 30 to 35 biotech IPOs this year, a significant jump.
But the window is selective. Investors aren't buying everything that moves. They want clinical-stage companies with real data, clear catalysts, and management teams that have done this before. Seaport checks every box.
The CNS angle adds extra intrigue. A wave of blockbuster drugs will lose patent protection between 2025 and 2030, and big pharma desperately needs to refill its pipeline. Neuroscience, long considered too risky for most acquirers, is suddenly looking attractive again. Novartis recently partnered with a brain-delivery platform startup called Sironax. J&J continues expanding its CNS franchise. The M&A backdrop is giving public investors confidence that even if a CNS biotech stumbles in trials, a buyout could still bail them out.
That kind of exit activity acts like a safety net under IPO investors.
The Risks Nobody Wants to Talk About
Let's be honest: this is still a pre-Phase 3 company valued near $1 billion at IPO. That's a lot of faith baked into early-stage science.
CNS trials are notoriously unpredictable. Depression studies, in particular, are plagued by high placebo response rates (patients who get sugar pills often improve significantly, making it hard to prove the drug itself works). Seaport knows this; they've published meta-analyses on placebo effects in depression and anxiety trials and claim to be designing their studies to minimize the problem. Whether that works in practice is another question entirely.
The competitive landscape is also getting crowded. Sage and Biogen have zuranolone, their own oral neurosteroid for depression. Axsome's Auvelity is already on the market. COMPASS Pathways is pushing psilocybin therapy through Phase 3. J&J's Spravato (esketamine nasal spray) set the benchmark for rapid-acting treatments. Seaport isn't entering an empty field; it's joining a race that's well underway.
And while $255 million sounds like a war chest, CNS trials are expensive and long. This capital likely funds the company through its key Phase 2 readouts, but probably not all the way through registration. A follow-on offering is almost certainly in the future.
What This IPO Really Means
Seaport's blockbuster debut isn't just good news for one company. It's a signal flare for the entire neuroscience sector. For years, "CNS biotech" was a phrase that made venture capitalists flinch. Now a clinical-stage brain drug company just raised a quarter billion dollars at the top of its range, backed by Goldman Sachs and the team that sold Karuna for $14 billion.
The real test comes when Phase 2 depression data drops. Until then, Seaport is trading on trust: trust in the platform, trust in the team, and trust that Wall Street's renewed love affair with brain drugs isn't just a fling.
Deals & M&A
4 min read
The Italian Family That Just Spent $4.1 Billion to Break Into America
A 107-year-old Italian family pharma just dropped $4.1 billion on a Florida rare disease company, paying roughly three times its own annual revenue. The deal gives Angelini instant access to the U.S. market and a portfolio generating nearly $600 million a year.
